Who
David L. Lacey
Director
Company insider
Files Form 4 as: Director, Arcus Biosciences; Director, Nurix Therapeutics; Director, Atreca; Director, Unity Biotechnology.
In numbers
- Trades disclosed
- 29
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 20 Jun 2019
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —5,700 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,900 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,900 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —5,700 at $0.00 | filing |
| 15 May 2026filed 15 May 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,250 at $0.00 | filing |
| 15 May 2026filed 15 May 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,250 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,300 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —13,300 at $0.00 | filing |
| 19 May 2025filed 19 May 2025 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 23 Jan 2025filed 27 Jan 2025 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —8,400 at $0.00 | filing |
| 20 May 2024filed 20 May 2024 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,500 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —6,800 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | Atrecaoption or derivative | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 4 May 2023filed 4 May 2023 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,800 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —4,100 at $0.00 | filing |
| 8 Jun 2022filed 10 Jun 2022 | Atrecaoption or derivative | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.